Picture of Amplia Therapeutics logo

ATX — Amplia Therapeutics News Story

0.000.00%
au flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapSucker Stock

Australia's Amplia Therapeutics hits over 1-month high on progress to drug trials

** Shares of drug developer Amplia Therapeutics  ATX.AX 
jump as much as 15.6% to A$0.185, their highest since Dec. 3,
2021
    ** Co says a contract manufacturer has completed
manufacturing of its clinical-stage drug candidate AMP945, a
pancreatic cancer and lung fibrosis drug  urn:newsml:reuters.com:*:nASX15gs1t 
    ** Mid-stage clinical trials for the drug scheduled to begin
in 2022 
    ** Co has also doubled the scale at which AMP945 can be
manufactured under 'good manufacturing practice' conditions
    ** Co has found that AMP945 can be stored for more than 24
months without detectable deterioration, which supports
commercial development of the drug 
    ** ATX set for its biggest intraday gain since Dec. 21, 2021
    ** Stock had lost 3% this year, as of last close 

 (Reporting by Harshita Swaminathan in Bengaluru)
 ((Harshita.Swaminathan@thomsonreuters.com))

Recent news on Amplia Therapeutics

See all news